450results about How to "Increase drug concentration" patented technology

The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component, alternatively, can take the role of a drug. The patent further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The patent finally reveals suitable methods and favourable conditions for carrier manufacturing and application.

A delivery system for the delivery of a salt of meptazinol or meptazinol precursor which increases the bioavailability of meptanizol by an effective amount to provide analgesic relief is disclosed. One embodiment of the delivery system is a transdermal device which increases the skin flux of meptazinol by an effective amount to provide analgesic relief. Also disclosed are methods of providing analgesic relief.

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and / or biavailability in a use environment.

The present invention provides human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Enterococcus.

The invention relates to the technical field of medicines, and in particular relates to a micro-emulsion thermosensitive gel for skin wound healing and a preparation method thereof. The micro-emulsion thermosensitive gel disclosed by the invention is composed of medicines, oil phase, a surfactant, a cosurfactant, a gel matrix and water, wherein the medicines are selected from resveratrol, paeonol and matrine. Proved by animal experiments, the prepared micro-emulsion thermosensitive gel has the characteristics of nearly no irritation to skin, safety in use, large percutaneous infiltration quantity, high percutaneous infiltration rate, long retention time of the micro-emulsion gel in the skin, high medicine concentration in the skin, good slow-release effect and good effect of promoting the healing of skin wound injury. The micro-emulsion thermosensitive gel disclosed by the invention has the advantages of simpleness in preparation method, low cost, convenience and safety in use and capability of effectively promoting the skin wound healing. According to the invention, a novel dosage form is provided for treating the skin wound.

The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of viral infections.

The invention relates to a tenofovir cyclic phosphonate compound having a structure represented by a formula I and a pharmaceutically acceptable salt thereof, and preparation methods and applications thereof, wherein the compound represented by the formula I is a tenofovir pro-drug having a liver targeting character and is used for treatment of hepatitis B and resistance of human immunodeficiency virus infection.

The invention provides a photosensitive liposome with encapsulated water-soluble medicament, which is composed of temperature-sensitive phospholipid, cholesterol and long circulation material and hollow gold nanoparticle, wherein, the hollow gold nanoparticle has a characteristic absorption peak at the near infrared zone with the wavelength of 700-900 nm, and the particle size distribution of the hollow gold nanoparticle is in the range of 20-100 nm. According to the invention, a brand new photosensitive liposome is composed by wrapping water-soluble medicament and hollow gold nanoparticle with temperature-sensitive liposome. Under the extraneous near infrared light, the wrapped hollow gold nanoparticle generates a photo-thermal treatment effect, simultaneously, the photo-thermal effect controls a rapid site-specific delivery of medicament in a large amount from the photosensitive liposome, thereby blood vessels in the tumour part can be damaged or the tumor cells can be killed effectively with a chemical treatment effect of the medicamen. The drug loaded liposome of the present invention realizes synchronous photo-thermal and medicament molecule treatment effect, and the treatment effect of disease such as tumour is substantially improved, and the invention has clinic applicability and real treatment meaning.

The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same.The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. (In the formula, is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group whereAr is an optionally substituted aryl group;X is —NH—, oxygen atom or sulfur atom;Y is —NR1—, oxygen atom, sulfur atom, sulfoxide or sulfone;Z is a single bond or —NR2—;R1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;R2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;l is an integer of from 0 to 15;m is an integer of 2 or 3; andn is an integer of from 0 to 3).The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

The invention discloses compound timicosin oral liquid, which comprises the following raw materials in percentage by weight: 5 to 40 percent of timicosin, 2 to 20 percent of astragalus polysaccharide, 2 to 20 percent of chlorogenic acid, 2 to 15 percent of indigowoad root polysaccharide, 4 to 40 percent of chlorogenic acid cosolvent, 0.5 to 2 percent of chelating agent, 0 to 25 percent of timicosin cosolvent, 0.9 to 10 percent of timicosin solvent, 0.004 to 0.01 percent of antioxidant, 0.02 to 0.1 percent of preservative, and 16 to 85 percent of distilled water. The timicosin is matched with the chlorogenic acid, the astragalus polysaccharide and the extract of indigowoad root to perform the complementary effects of different action mechanisms, so that the stronger effects of resisting bacteria and viruses and improving immunity are realized.